Viridian Therapeutics Shares Fall Despite Positive Phase 3 Trial Results

Viridian Therapeutics (VRDN) reported successful results from its Phase 3 REVEAL-1 trial for elegrobart, a treatment for thyroid eye disease. The study met its primary endpoint, showing significant proptosis responder rates of 54% and 63% across different dosing regimens, compared to just 18% for the placebo group. Despite these positive clinical outcomes, shares of the biotechnology company experienced a decline during Monday's trading session. Market analysts suggest the downward movement may be a "sell the news" reaction or reflects investor caution regarding competition in the sector. The trial results are a critical milestone for the company's pipeline, yet the immediate market response remains negative. Investors continue to monitor the company's progress toward regulatory filings and potential commercialization.